增加食纤维摄入量用于2型糖尿病管理:系统性审查
Douglas Nitzke1, Juliana Czermainski2, Carolina Rosa1
1Department of Nutrition, Centro Universitário CESUCA, Cachoeirinha 94935-630, Brazil.
World journal of diabetes
|May 20, 2024
概括
增加食纤维 (DF) 摄入量可显著改善2型糖尿病患者的血糖控制和体重管理. 包括补充剂和高纤维饮食在内的DF干预措施为管理这种慢性疾病提供了有价值的策略.
科学领域:
- 营养科学 营养科学
- 代谢障碍 代谢障碍 代谢障碍
- 公共卫生 公共卫生
背景情况:
- 2型糖尿病是一种全球性慢性疾病,与饮食不良和不活动有关.
- 食纤维 (DF) 摄入与改善血糖控制和体重管理有关.
- 了解DF的作用对于管理2型糖尿病 (T2DM) 至关重要.
研究的目的:
- 评估饮食纤维干预措施对T2DM管理的有效性.
- 综合证据证实了增加的DF摄入量对T2DM结果的影响.
主要方法:
- 进行了系统的文献审查.
- 根据特定的纳入和排除标准,包括了26项研究.
- 审查的重点是DF摄入量与T2DM管理之间的关联.
主要成果:
- 干预措施包括高DF饮食,高DF补充剂和高DF饮食与阿卡尔相结合.
- 大多数研究报告了增加DF摄入量对T2DM患者的积极影响.
- 在血糖控制和体重管理方面观察到关键的改善.
结论:
- 食纤维是T2DM治疗和改善健康结果的有益策略.
- 增加DF摄入量可以提高生活质量,减少与糖尿病相关的并发症和死亡率.
- 通过补充剂或强化食品,DF有效控制HbA1c,血糖,脂质和体重.
相关概念视频
Diabetes: Management and Pharmacotherapy
265
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
265
Carbohydrate Metabolism
11.0K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.0K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Irritable Bowel Syndrome III: Medical and Nursing Management
195
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
195
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
173
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
173


